LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and…
Read the full articleYou might also wanna read
Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi
Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other
BioSpace·2d ago
Biogen (BIIB) Unveils Efficacy Data for LEQEMBI Autoinjector at AAIC 2026
Related Stocks: BIIB
GuruFocus·4d ago
FDA clears at-home start dose for Alzheimer's drug Leqembi
FDA clears at-home start dose for Alzheimer's drug Leqembi Phil.Taylor Tue, 14/07/2026 - 08:36
pharmaphorum·2d ago
Canada's Drug Agency recommends funding lecanemab for early-stage Alzheimer's disease
Canada's Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer's dis
Narcity·9h ago
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
GuruFocus·2d ago
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
Conditions : Systemic Lupus Erythematosus Interventions : Combination Product: Anifrolumab: SC formulation via AI; Combination Product: Anif
clinicaltrials.gov·9d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.